TD Cowen analyst Dan Brennan raised the firm’s price target on Illumina (ILMN) to $89 from $86 and keeps a Hold rating on the shares. The firm says that against a difficult macro, Illumina is delivering good execution and maintaining EPS growth despite idiosyncratic China and NIH spend headwinds. Guidance was reduced though a cut was expected, and underneath there are positives and strong cost out, TD Cowen argues.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target lowered to $85 from $120 at JPMorgan
- Illumina price target lowered to $114 from $122 at Guggenheim
- Illumina’s Financial Outlook: Hold Rating Amidst Export Bans and Tariff Challenges
- Illumina Reports Q1 2025 Financial Results Amid Challenges
- Closing Bell Movers: Pinterest jumps 15%, Toast up 7% after earnings